Cohbar Inc (CWBR) USD0.001
CohBar, Inc. (CohBar) is a clinical-stage biotechnology company. The Company is focused on the research and development of mitochondria based therapeutics (MBTs), an emerging class of drugs for the treatment of chronic and age-related diseases. The Company’s lead compound, CB4211, is in the Phase I b stage of a Phase I a/1b clinical trial for nonalcoholic steatohepatitis (NASH) and obesity. In addition, CohBar has four preclinical programs, including one in fibrotic diseases, one in acute respiratory distress syndrome (ARDS) and two in cancer. The Company’s pipeline is focused on identifying, assessing and optimizing new analogs of biologically active MDPs. Its pipeline includes peptide analogs of mitochondrial-derived peptides (MDPs) in different stages of research evaluation as potential MBTs, and one MBT in clinical development.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.